Table 4.
Chemoradiation with local excision
| Authors or study (reference) | Accrual year | N | Age (y)* | Median f/u (mo) | Stage | RT |
|---|---|---|---|---|---|---|
|
| ||||||
| Kim et al (95) | 1994–2000 | 26 | Mean 63 (44–90) | 19 | T2–3N0–1 | 45 Gy in 25 fx |
| Bonnen et al (96) | 1990–2002 | 26 | 60 | 46 | T3N0–1 | 45 Gy in 25 |
| Lezoche et al (97) | 1997–2004 | 50 | 66 (58–70) | 9.6 y | cT2N0 | fx ± boost to 52.5 Gy 50.4 Gy in 28 fx |
| Nair et al (98) | 1994–2006 | 44 | 69 (43–89) | 64 | T2–3N0–1 | 50.4 Gy in 28 fx |
| ACOSOG Z6041 (99) | 2006–2009 | 79 | 62 (30–83) | 56 | T2N0 | 54 Gy @ 180 cGy/fx |
| CARTS (100) | 2010–2012 | 55 | 64 (39–82) | 17 | cT1–3N0 | 50 Gy in 25 fx; 50.4 Gy in 28 fx |
| Chemo | LE criteria† | LR, n (%) | DM, n (%) | OS (%) | DFS (%) |
|---|---|---|---|---|---|
|
| |||||
| 5-FU | ypT0 | 1 (3.8) | 0 | N/A | N/A |
| 5-FU | N/A | 2 (7.7) | 3 (11.5) | N/A | 5-y = 80 |
| 5-FU | ypT0–2 | 4 (8) | 2 (4) | OS = 72; CSS = 89 (at end of f/u) |
N/A |
| 5-FU | N/A | 4 (9.1) | 5 (11.4) | 5-y = 81–84 | N/A |
| Cape-ox | ypT0–2 | 3 (3.8) | 5 (6.3) | N/A | 3-y = 88.2 |
| Capecitabine | ypT0–1 | 4 (7.3) | 1 (1.8) | N/A | N/A |
Abbreviations: Cape-ox = capecitabine/oxaliplatin; CR = complete response; CSS = cancer-specific survival; DM = distant metastases; LE = local excision; LR = local recurrence. Other abbreviations as in Table 2.
*
Age expressed as median unless otherwise noted. Values in parentheses are range.
†
Acceptable pathologic staging after neoadjuvant chemoradiation and local excision without recommendation for radical surgery.